Ipsen claims pos­i­tive PhI­II in drug once owned by Mer­ri­mack, whose shares jump pend­ing pos­si­ble nine-fig­ure pay­out

Ipsen an­nounced a pos­i­tive late-stage read­out ear­ly Wednes­day, re­sult­ing in a de­funct biotech po­ten­tial­ly re­ceiv­ing the big bucks.

The French phar­ma an­nounced that the pri­ma­ry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER